<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02287584</url>
  </required_header>
  <id_info>
    <org_study_id>D4904020</org_study_id>
    <secondary_id>JapicCTI-142688</secondary_id>
    <nct_id>NCT02287584</nct_id>
  </id_info>
  <brief_title>Confirmatory Study of DSP-5423P in Patients With Schizophrenia</brief_title>
  <official_title>Confirmatory Study of DSP-5423P in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the efficacy of DSP-5423P compared with&#xD;
      placebo in patients with schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PANSS Total Score From Baseline at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>The Positive and Negative Syndrome Scale (PANSS) is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and 3 subscales: the Positive subscale assesses hallucinations, delusions, and related symptoms; the Negative subscale assesses emotional withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Who Achieve a Response, Defined as 20% or Greater Improvement From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6</measure>
    <time_frame>Week 6 (LOCF)</time_frame>
    <description>The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and 3 subscales: the Positive subscale assesses hallucinations, delusions, and related symptoms; the Negative subscale assesses emotional withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine a total score. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.&#xD;
The Last Observation Carried Forward (LOCF) endpoint is defined as the last data captured on Day 1 through 7 days after the final application of DSP-5423P.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Continuation Rate at 28 Weeks and 52 Weeks</measure>
    <time_frame>Open-Week 28 and Open-Week 52 in the open-label treatment phase</time_frame>
    <description>Percentage of subjects who stay the study up to 28 weeks (196 days, all countries), and 52 weeks (364 days, in Japan) and its 95% confidence interval.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">580</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>DSP-5423P Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Percutaneous DSP-5423P Placebo was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DSP-5423P 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous DSP-5423P 40mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DSP-5423P 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous DSP-5423P 80mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DSP-5423P Placebo-to-Flex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous Subjects received DSP-5423P Placebo once daily for 6 weeks in the double-blind treatment phase. In the open-label treatment phase, DSP-5423P was applied as flexible dose (40, 60, or 80 mg) once daily for 28 weeks (outside Japan) or 52 weeks (in Japan). The study drug was applied to the back, chest, or abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DSP-5423P Active-to-Flex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous Subjects received DSP-5423P 40mg or 80mg once daily for 6 weeks in the double-blind treatment phase. In the open-label treatment phase, DSP-5423P was applied as flexible dose (40, 60, or 80 mg) once daily for 28 weeks (outside Japan) or 52 weeks (in Japan). The study drug was applied to the back, chest, or abdomen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSP-5423P Placebo</intervention_name>
    <description>DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily</description>
    <arm_group_label>DSP-5423P Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSP-5423P 40mg</intervention_name>
    <description>DSP-5423P 40mg was applied to the subject's back, chest, or abdomen once daily</description>
    <arm_group_label>DSP-5423P 40mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSP-5423P 80mg</intervention_name>
    <description>DSP-5423P 80mg was applied to the subject's back, chest, or abdomen once daily</description>
    <arm_group_label>DSP-5423P 80mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSP-5423P Placebo-to-Flex</intervention_name>
    <description>DSP-5423P Placebo:&#xD;
DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily&#xD;
DSP-5423P Flex:&#xD;
DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily</description>
    <arm_group_label>DSP-5423P Placebo-to-Flex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSP-5423P Active-to-Flex</intervention_name>
    <description>DSP-5423P Active:&#xD;
DSP-5423P 40mg or 80mg was applied to the subject's back, chest, or abdomen once daily&#xD;
DSP-5423P Flex:&#xD;
DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily</description>
    <arm_group_label>DSP-5423P Active-to-Flex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have schizophrenia diagnosed by DSM-5, diagnostic criteria&#xD;
&#xD;
          -  Patients who are aged 18 years or older at informed consent&#xD;
&#xD;
          -  Patient understands the objectives and procedures of the study and who provide written&#xD;
             voluntarily consent to participate in the study, etc.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who fall under a contraindication listed in the blonanserin (LONASEN) package&#xD;
             insert&#xD;
&#xD;
          -  Patients with Parkinson disease&#xD;
&#xD;
          -  Patients who previously received blonanserin, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Director, Drug Development Division</last_name>
    <role>Study Director</role>
    <affiliation>Sumitomo Dainippon Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>3 Sites</name>
      <address>
        <city>Beijing, Etc.</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>53 Sites</name>
      <address>
        <city>Tokyo Etc.</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>7 Sites</name>
      <address>
        <city>Seoul, Etc.</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>14 Sites</name>
      <address>
        <city>Kuala Lumpur, Etc.</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>9 Sites</name>
      <address>
        <city>Manila, etc.</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>8 Sites</name>
      <address>
        <city>Smolensk, Etc</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>6 Sites</name>
      <address>
        <city>Taipei, Etc.</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>8 Sites</name>
      <address>
        <city>Poltava, Etc</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 6, 2014</study_first_submitted>
  <study_first_submitted_qc>November 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2014</study_first_posted>
  <results_first_submitted>August 31, 2020</results_first_submitted>
  <results_first_submitted_qc>December 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 23, 2020</results_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT02287584/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT02287584/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were conducted in 8 countries/region between December 2014 and October 2018.</recruitment_details>
      <pre_assignment_details>In this study, 675 subjects provided informed consent, 580 of 606 subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DSP-5423P Placebo</title>
          <description>Percutaneous DSP-5423P Placebo was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.&#xD;
DSP-5423P Placebo: DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily</description>
        </group>
        <group group_id="P2">
          <title>DSP-5423P 40mg</title>
          <description>Percutaneous DSP-5423P 40mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.&#xD;
DSP-5423P 40mg: DSP-5423P 40mg was applied to the subject's back, chest, or abdomen once daily</description>
        </group>
        <group group_id="P3">
          <title>DSP-5423P 80mg</title>
          <description>Percutaneous DSP-5423P 80mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.&#xD;
DSP-5423P 80mg: DSP-5423P 80mg was applied to the subject's back, chest, or abdomen once daily</description>
        </group>
        <group group_id="P4">
          <title>DSP-5423P Placebo-to-Flex</title>
          <description>Percutaneous DSP-5423P Placebo was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen once daily.&#xD;
DSP-5423P 20 mg patches and DSP-5423P 40 mg patches were used in the open-label treatment phase. One or two patches of DSP-5423P was/were applied once daily to subjects for a further 28 weeks (outside Japan) or 52 weeks (in Japan). The initial dose of DSP-5423P in the open-label treatment phase was 40 mg/day. After DSP-5423P 40 mg/day application for about 1 week, DSP-5423P could be applied as flexible dose within a range from 40 mg/day to 80 mg/day.</description>
        </group>
        <group group_id="P5">
          <title>DSP-5423P 40mg-to-Flex</title>
          <description>Percutaneous DSP-5423P 40mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen once daily.&#xD;
DSP-5423P 20 mg patches and DSP-5423P 40 mg patches were used in the open-label treatment phase. One or two patches of DSP-5423P was/were applied once daily to subjects for a further 28 weeks (outside Japan) or 52 weeks (in Japan). The initial dose of DSP-5423P in the open-label treatment phase was 40 mg/day. After DSP-5423P 40 mg/day application for about 1 week, DSP-5423P could be applied as flexible dose within a range from 40 mg/day to 80 mg/day.</description>
        </group>
        <group group_id="P6">
          <title>DSP-5423P 80mg-to-Flex</title>
          <description>Percutaneous DSP-5423P 80mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen once daily.&#xD;
DSP-5423P 20 mg patches and DSP-5423P 40 mg patches were used in the open-label treatment phase. One or two patches of DSP-5423P was/were applied once daily to subjects for a further 28 weeks (outside Japan) or 52 weeks (in Japan). The initial dose of DSP-5423P in the open-label treatment phase was 40 mg/day. After DSP-5423P 40 mg/day application for about 1 week, DSP-5423P could be applied as flexible dose within a range from 40 mg/day to 80 mg/day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>the Double-blind Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="190"/>
                <participants group_id="P2" count="196"/>
                <participants group_id="P3" count="194"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
                <participants group_id="P2" count="149"/>
                <participants group_id="P3" count="161"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>other reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>the Open-label Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="138"/>
                <participants group_id="P5" count="149"/>
                <participants group_id="P6" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="131"/>
                <participants group_id="P5" count="143"/>
                <participants group_id="P6" count="157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="81"/>
                <participants group_id="P5" count="87"/>
                <participants group_id="P6" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="57"/>
                <participants group_id="P5" count="62"/>
                <participants group_id="P6" count="57"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not receive drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="29"/>
                <participants group_id="P6" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>other reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>modified Intention-to-treat (mITT) population</population>
      <group_list>
        <group group_id="B1">
          <title>DSP-5423P Placebo</title>
          <description>Percutaneous DSP-5423P Placebo was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.&#xD;
DSP-5423P Placebo: DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily</description>
        </group>
        <group group_id="B2">
          <title>DSP-5423P 40mg</title>
          <description>Percutaneous DSP-5423P 40mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.&#xD;
DSP-5423P 40mg: DSP-5423P 40mg was applied to the subject's back, chest, or abdomen once daily</description>
        </group>
        <group group_id="B3">
          <title>DSP-5423P 80mg</title>
          <description>Percutaneous DSP-5423P 80mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.&#xD;
DSP-5423P 80mg: DSP-5423P 80mg was applied to the subject's back, chest, or abdomen once daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="189"/>
            <count group_id="B2" value="196"/>
            <count group_id="B3" value="192"/>
            <count group_id="B4" value="577"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.5" spread="13.67"/>
                    <measurement group_id="B2" value="40.7" spread="13.34"/>
                    <measurement group_id="B3" value="40.7" spread="14.35"/>
                    <measurement group_id="B4" value="41.0" spread="13.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="180"/>
                    <measurement group_id="B4" value="541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="234"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="114"/>
                    <measurement group_id="B4" value="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="189"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="192"/>
                    <measurement group_id="B4" value="577"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="165"/>
                    <measurement group_id="B4" value="493"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Positive and Negative Syndrome Scale (PANSS) total score</title>
          <description>The PANSS is comprised of 30 items and 3 subscales: the Positive subscale assesses hallucinations, delusions, and related symptoms; the Negative subscale assesses emotional withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1 to 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99.5" spread="13.84"/>
                    <measurement group_id="B2" value="101.6" spread="15.55"/>
                    <measurement group_id="B3" value="101.5" spread="14.76"/>
                    <measurement group_id="B4" value="100.9" spread="14.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in PANSS Total Score From Baseline at Week 6</title>
        <description>The Positive and Negative Syndrome Scale (PANSS) is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and 3 subscales: the Positive subscale assesses hallucinations, delusions, and related symptoms; the Negative subscale assesses emotional withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.</description>
        <time_frame>Week 6</time_frame>
        <population>modified Intention-to-treat (mITT) population; Change in PANSS Total Score Using Mixed Model for Repeated Measures in the Double-Blind Treatment Phase</population>
        <group_list>
          <group group_id="O1">
            <title>DSP-5423P Placebo</title>
            <description>Percutaneous DSP-5423P Placebo was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.&#xD;
DSP-5423P Placebo: DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily</description>
          </group>
          <group group_id="O2">
            <title>DSP-5423P 40mg</title>
            <description>Percutaneous DSP-5423P 40mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.&#xD;
DSP-5423P 40mg: DSP-5423P 40mg was applied to the subject's back, chest, or abdomen once daily</description>
          </group>
          <group group_id="O3">
            <title>DSP-5423P 80mg</title>
            <description>Percutaneous DSP-5423P 80mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.&#xD;
DSP-5423P 80mg: DSP-5423P 80mg was applied to the subject's back, chest, or abdomen once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PANSS Total Score From Baseline at Week 6</title>
          <description>The Positive and Negative Syndrome Scale (PANSS) is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and 3 subscales: the Positive subscale assesses hallucinations, delusions, and related symptoms; the Negative subscale assesses emotional withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.</description>
          <population>modified Intention-to-treat (mITT) population; Change in PANSS Total Score Using Mixed Model for Repeated Measures in the Double-Blind Treatment Phase</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="196"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline mean(SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" spread="13.84"/>
                    <measurement group_id="O2" value="101.6" spread="15.55"/>
                    <measurement group_id="O3" value="101.5" spread="14.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.8" spread="1.47"/>
                    <measurement group_id="O2" value="-16.4" spread="1.43"/>
                    <measurement group_id="O3" value="-21.3" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Using Mixed Model for Repeated Measures</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>adjusted p value, Hochberg procedure</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.6</ci_lower_limit>
            <ci_upper_limit>-1.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>adjusted p-value, Hochberg procedure</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.4</ci_lower_limit>
            <ci_upper_limit>-6.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Who Achieve a Response, Defined as 20% or Greater Improvement From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6</title>
        <description>The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and 3 subscales: the Positive subscale assesses hallucinations, delusions, and related symptoms; the Negative subscale assesses emotional withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine a total score. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.&#xD;
The Last Observation Carried Forward (LOCF) endpoint is defined as the last data captured on Day 1 through 7 days after the final application of DSP-5423P.</description>
        <time_frame>Week 6 (LOCF)</time_frame>
        <population>modified Intention-to-treat (mITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>DSP-5423P Placebo</title>
            <description>Percutaneous DSP-5423P Placebo was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.&#xD;
DSP-5423P Placebo: DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily</description>
          </group>
          <group group_id="O2">
            <title>DSP-5423P 40mg</title>
            <description>Percutaneous DSP-5423P 40mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.&#xD;
DSP-5423P 40mg: DSP-5423P 40mg was applied to the subject's back, chest, or abdomen once daily</description>
          </group>
          <group group_id="O3">
            <title>DSP-5423P 80mg</title>
            <description>Percutaneous DSP-5423P 80mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.&#xD;
DSP-5423P 80mg: DSP-5423P 80mg was applied to the subject's back, chest, or abdomen once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Who Achieve a Response, Defined as 20% or Greater Improvement From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6</title>
          <description>The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and 3 subscales: the Positive subscale assesses hallucinations, delusions, and related symptoms; the Negative subscale assesses emotional withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine a total score. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.&#xD;
The Last Observation Carried Forward (LOCF) endpoint is defined as the last data captured on Day 1 through 7 days after the final application of DSP-5423P.</description>
          <population>modified Intention-to-treat (mITT) population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="196"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;=20% improvement from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=30% improvement from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=40% improvement from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=50% improvement from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Continuation Rate at 28 Weeks and 52 Weeks</title>
        <description>Percentage of subjects who stay the study up to 28 weeks (196 days, all countries), and 52 weeks (364 days, in Japan) and its 95% confidence interval.</description>
        <time_frame>Open-Week 28 and Open-Week 52 in the open-label treatment phase</time_frame>
        <population>Open-label population: all subjects who applied DSP-5423P at least once in the open-label treatment phase.</population>
        <group_list>
          <group group_id="O1">
            <title>DSP-5423P Placebo-to-Flex</title>
            <description>Percutaneous Subjects received DSP-5423P Placebo once daily for 6 weeks in the double-blind treatment phase. In the open-label treatment phase, DSP-5423P was applied as flexible dose (40, 60, or 80 mg) once daily for 28 weeks (outside Japan) or 52 weeks (in Japan). The study drug was applied to the back, chest, or abdomen.</description>
          </group>
          <group group_id="O2">
            <title>DSP-5423P 40 Mg-to-Flex</title>
            <description>Percutaneous Subjects received DSP-5423P 40 mg once daily for 6 weeks in the double-blind treatment phase. In the open-label treatment phase, DSP-5423P was applied as flexible dose (40, 60, or 80 mg) once daily for 28 weeks (outside Japan) or 52 weeks (in Japan). The study drug was applied to the back, chest, or abdomen.</description>
          </group>
          <group group_id="O3">
            <title>DSP-5423P 80 Mg-to-Flex</title>
            <description>Percutaneous Subjects received DSP-5423P 80 mg once daily for 6 weeks in the double-blind treatment phase. In the open-label treatment phase, DSP-5423P was applied as flexible dose (40, 60, or 80 mg) once daily for 28 weeks (outside Japan) or 52 weeks (in Japan). The study drug was applied to the back, chest, or abdomen.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Continuation Rate at 28 Weeks and 52 Weeks</title>
          <description>Percentage of subjects who stay the study up to 28 weeks (196 days, all countries), and 52 weeks (364 days, in Japan) and its 95% confidence interval.</description>
          <population>Open-label population: all subjects who applied DSP-5423P at least once in the open-label treatment phase.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="143"/>
                <count group_id="O3" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>28 weeks (196 days, all countries)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="131"/>
                    <count group_id="O2" value="143"/>
                    <count group_id="O3" value="157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.4" lower_limit="55.7" upper_limit="72.2"/>
                    <measurement group_id="O2" value="62.9" lower_limit="54.5" upper_limit="70.3"/>
                    <measurement group_id="O3" value="70.7" lower_limit="62.9" upper_limit="77.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52 weeks (364 days, in Japan)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" lower_limit="23.4" upper_limit="63.6"/>
                    <measurement group_id="O2" value="51.5" lower_limit="33.5" upper_limit="66.9"/>
                    <measurement group_id="O3" value="50.0" lower_limit="34.2" upper_limit="63.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 58 weeks</time_frame>
      <desc>Safety population in the double-blind phase; The safety population consisted of all subjects who were randomized and applied the study drug at least once during the study.&#xD;
DSP-5423P dosed population in the open-label population; The DSP-5423P dosed population consisted of all subjects who applied DSP-5423P at least once during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>DSP-5423P Placebo</title>
          <description>Percutaneous DSP-5423P Placebo was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.&#xD;
DSP-5423P Placebo: DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily</description>
        </group>
        <group group_id="E2">
          <title>DSP-5423P 40mg</title>
          <description>Percutaneous DSP-5423P 40mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.&#xD;
DSP-5423P 40mg: DSP-5423P 40mg was applied to the subject's back, chest, or abdomen once daily</description>
        </group>
        <group group_id="E3">
          <title>DSP-5423P 80mg</title>
          <description>Percutaneous DSP-5423P 80mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.&#xD;
DSP-5423P 80mg: DSP-5423P 80mg was applied to the subject's back, chest, or abdomen once daily</description>
        </group>
        <group group_id="E4">
          <title>DSP-5423P Placebo-to-Flex</title>
          <description>Percutaneous Subjects received DSP-5423P Placebo once daily for 6 weeks in the double-blind treatment phase. In the open-label treatment phase, DSP-5423P was applied as flexible dose (40, 60, or 80 mg) once daily for 28 weeks (outside Japan) or 52 weeks (in Japan). The study drug was applied to the back, chest, or abdomen.&#xD;
DSP-5423P Placebo-to-Flex: DSP-5423P Placebo:&#xD;
DSP-5423P Placebo was applied to the subject's back, chest, or abdomen once daily&#xD;
DSP-5423P Flex:&#xD;
DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily</description>
        </group>
        <group group_id="E5">
          <title>DSP-5423P 40mg-to-Flex</title>
          <description>Percutaneous Subjects received DSP-5423P 40mg once daily for 6 weeks in the double-blind treatment phase. In the open-label treatment phase, DSP-5423P was applied as flexible dose (40, 60, or 80 mg) once daily for 28 weeks (outside Japan) or 52 weeks (in Japan). The study drug was applied to the back, chest, or abdomen.&#xD;
DSP-5423P Active-to-Flex: DSP-5423P Active:&#xD;
DSP-5423P 40mg or 80mg was applied to the subject's back, chest, or abdomen once daily&#xD;
DSP-5423P Flex:&#xD;
DSP-5423P 20mg, 60mg or 80mg was applied to the subject's back, chest, or abdomen once daily</description>
        </group>
        <group group_id="E6">
          <title>DSP-5423P 80mg-to-Flex</title>
          <description>Percutaneous Subjects received DSP-5423P 80mg once daily for 6 weeks in the double-blind treatment phase. In the open-label treatment phase, DSP-5423P was applied as flexible dose (40, 60, or 80 mg) once daily for 28 weeks (outside Japan) or 52 weeks (in Japan). The study drug was applied to the back, chest, or abdomen.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 19.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="194"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="29" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bartholin's abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Catatonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Psychiatric symptom</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="190"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="131"/>
                <counts group_id="E5" events="11" subjects_affected="10" subjects_at_risk="196"/>
                <counts group_id="E6" events="11" subjects_affected="10" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Social stay hospitalisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 19.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="190"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="194"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="131"/>
                <counts group_id="E5" subjects_affected="108" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="111" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="190"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="196"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="194"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E5" events="11" subjects_affected="8" subjects_at_risk="196"/>
                <counts group_id="E6" events="18" subjects_affected="13" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="196"/>
                <counts group_id="E6" events="12" subjects_affected="10" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="190"/>
                <counts group_id="E2" events="17" subjects_affected="11" subjects_at_risk="196"/>
                <counts group_id="E3" events="33" subjects_affected="18" subjects_at_risk="194"/>
                <counts group_id="E4" events="12" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E5" events="22" subjects_affected="12" subjects_at_risk="196"/>
                <counts group_id="E6" events="43" subjects_affected="23" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="196"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="194"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E5" events="15" subjects_affected="14" subjects_at_risk="196"/>
                <counts group_id="E6" events="20" subjects_affected="19" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="190"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="196"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="194"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="131"/>
                <counts group_id="E5" events="27" subjects_affected="14" subjects_at_risk="196"/>
                <counts group_id="E6" events="32" subjects_affected="25" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="190"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="194"/>
                <counts group_id="E4" events="10" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E5" events="14" subjects_affected="11" subjects_at_risk="196"/>
                <counts group_id="E6" events="7" subjects_affected="5" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="190"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="194"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="131"/>
                <counts group_id="E5" events="13" subjects_affected="13" subjects_at_risk="196"/>
                <counts group_id="E6" events="13" subjects_affected="13" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle rigidity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="194"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="196"/>
                <counts group_id="E6" events="12" subjects_affected="11" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="190"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="196"/>
                <counts group_id="E3" events="22" subjects_affected="19" subjects_at_risk="194"/>
                <counts group_id="E4" events="14" subjects_affected="11" subjects_at_risk="131"/>
                <counts group_id="E5" events="27" subjects_affected="22" subjects_at_risk="196"/>
                <counts group_id="E6" events="34" subjects_affected="27" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Bradykinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="190"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="194"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="196"/>
                <counts group_id="E6" events="11" subjects_affected="11" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="190"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="196"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="194"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E5" events="21" subjects_affected="13" subjects_at_risk="196"/>
                <counts group_id="E6" events="35" subjects_affected="17" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="190"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="196"/>
                <counts group_id="E3" events="18" subjects_affected="17" subjects_at_risk="194"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="131"/>
                <counts group_id="E5" events="15" subjects_affected="14" subjects_at_risk="196"/>
                <counts group_id="E6" events="33" subjects_affected="27" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="190"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="196"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="194"/>
                <counts group_id="E4" events="28" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E5" events="32" subjects_affected="22" subjects_at_risk="196"/>
                <counts group_id="E6" events="29" subjects_affected="20" subjects_at_risk="194"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="190"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="196"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E5" events="13" subjects_affected="13" subjects_at_risk="196"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="194"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research</name_or_title>
      <organization>Sumitomo Dainippon Pharmaceutical</organization>
      <phone>+81-3-5159-2519</phone>
      <email>cc@ds-pharma.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

